All In Biotech

Drug Trial Radar · NCT02760797

A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

An Open-Label, Multicenter, Dose-Escalation Phase Ib Study With Expansion Phase to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of Emactuzumab and RO7009789 Administered in Combination in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 22, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

May 9, 2016

Primary completion

Apr 6, 2018

Study completion Apr 6, 2018

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 4, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics, and therapeutic activity of emactuzumab and RO7009789 administered in combination in participants with locally advanced or metastatic solid tumors that are not amenable to standard treatment. This study will be conducted in two parts: a dose-finding stage (Part I) and an expansion stage (Part II).

Conditions

  • Neoplasms

Interventions

  • EmactuzumabDrug

    Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.

  • RO7009789Drug

    RO7009789 will be administered IV every 3 weeks (every cycle).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Up to 6 weeks from Day (D) 1 of Cycle (C) 1 (cycle = 3 weeks)

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • University Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • Centre Leon Berard; Departement Oncologie Medicale

    Lyon, France

  • Institut Claudius Regaud; Departement Oncologie Medicale

    Toulouse, France

  • Institut Gustave Roussy; Sitep

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.